Sharps Technology (NASDAQ:STSS – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
Volatility & Risk
Sharps Technology has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
Valuation and Earnings
This table compares Sharps Technology and Delcath Systems’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sharps Technology | N/A | N/A | -$9.84 million | N/A | N/A |
| Delcath Systems | $2.07 million | 58.73 | -$47.68 million | ($2.97) | -1.67 |
Insider and Institutional Ownership
17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 14.1% of Sharps Technology shares are held by insiders. Comparatively, 21.1% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Sharps Technology and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sharps Technology | N/A | -103.10% | -76.46% |
| Delcath Systems | -2,308.86% | -563.60% | -111.13% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Sharps Technology and Delcath Systems, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sharps Technology | 0 | 0 | 1 | 0 | 3.00 |
| Delcath Systems | 0 | 0 | 4 | 0 | 3.00 |
Delcath Systems has a consensus target price of $18.50, indicating a potential upside of 273.74%. Given Delcath Systems’ higher probable upside, analysts plainly believe Delcath Systems is more favorable than Sharps Technology.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Sharps Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sharps Technology and related companies with MarketBeat.com's FREE daily email newsletter.
